succinobucol has been researched along with cilostazol in 1 studies
| Studies (succinobucol) | Trials (succinobucol) | Recent Studies (post-2010) (succinobucol) | Studies (cilostazol) | Trials (cilostazol) | Recent Studies (post-2010) (cilostazol) |
|---|---|---|---|---|---|
| 53 | 5 | 16 | 1,508 | 302 | 848 |
| Protein | Taxonomy | succinobucol (IC50) | cilostazol (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 0.4367 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 0.3285 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Douglas, JS | 1 |
1 review(s) available for succinobucol and cilostazol
| Article | Year |
|---|---|
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; ortho-Aminobenzoates; Pioglitazone; Platelet Aggregation Inhibitors; Probucol; Risk Factors; Stents; Tetrazoles; Thiazolidinediones; Trapidil; Treatment Outcome | 2007 |